Whoop raises $575M—Abbott, LeBron James, Cristiano Ronaldo among the investors
Whoop, a Boston-based wearable technologies company, has raised $575 million in new financing at a $10.1 billion valuation. Investors include Abbott, Mayo Clinic, LeBron James and Cristiano Ronaldo.
Whoop’s wearable devices are designed to provide users with 24/7 predictive insights based on their own health data. Features include an electrocardiogram feature approved by the U.S. Food and Drug Administration (FDA), blood pressure insights and a blood biomarker analysis. Advanced artificial intelligence models evaluate these data and provide detailed evaluations on the company’s smartphone app. These devices have no screen and were designed with fashion in mind.
To date, Whoop has more than 2.5 million users who pay an annual subscription fee.
“Our raise brings together the world’s most sophisticated investors, leading health institutions, and iconic global athletes behind the mission to unlock human performance and healthspan,” Will Ahmed, founder and CEO of Whoop, said in a statement. “We are building the personal health platform that people use to improve their health and livelihood.”
Whoop plans on using these new funds to expand its presence across Europe and other parts of the world. Additionally, this latest fundraising round—and the new relationship with Abbott—is designed to help the company ramp up its efforts to plan an even bigger role in healthcare going forward.
Cristiano Ronaldo, an investor in Whoop, wearing the company's device on his wrist.
One thing setting Whoop apart from other vendors in this space is the focus on high fashion and global culture. In addition to James and Ronaldo, other individual investors include golfer Rory McIlroy, former basketball player and announcer Reggie Miller, singer Niall Horan and entrepreneur/influencer Karen Wazen. Getting these celebrities on board is sure to help attract individuals who may not otherwise consider utilizing a wearable device.
“Whoop has become one of the most important tools I use to support my long-term health,” Ronaldo said in the same statement. “I am proud to participate in this round because I believe in the future we are building together. No other company has created a health platform this powerful that people are proud to wear.”
Whoop pushed back against FDA warning in 2025
The FDA sent Whoop a warning letter in 2025 about the marketing of the company’s technologies. The agency argued that Whoop failed to secure the proper regulatory approvals for its Blood Pressure Insights feature that tracks daily blood pressure estimates based on the user’s heart rate, sleep patterns and other factors.
From the FDA’s perspective, these are medical devices and should be treated as such. To Whoop, however, these devices are not medical devices.
“We respectfully disagree,” the company said at the time. “Blood Pressure Insights is a wellness feature, not a medical device. It’s designed to help you understand how your body responds to daily life, not to diagnose or treat any condition.”
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.